Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its proprietary PDAOAI drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026 in San Francisco on June 11. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has helped accelerate the development of two drug candidates from concept to investigational new drug filings in less than two years, significantly reducing the time and cost traditionally associated with pharmaceutical development.
The presentation will highlight several innovations underpinning the platform, including a proprietary “manifold folding” technique designed to improve semantic retrieval accuracy and reduce large language model hallucinations, as well as the indexing of approximately 28 million PubMed biomedical abstracts on Qdrant Cloud. Oncotelic said the platform leverages advanced vector search technologies to support large-scale biomedical research and accelerate oncology drug discovery efforts. For more details, visit the full press release.
This demonstration is significant because it underscores the potential of AI-driven platforms to transform the pharmaceutical industry by drastically cutting development timelines and costs. Traditional drug discovery can take over a decade and cost billions, but Oncotelic’s ability to move from concept to investigational new drug (IND) filings in under two years suggests a paradigm shift. The PDAOAI platform’s integration with Qdrant’s vector search technology enables efficient mining of vast biomedical literature, which is critical for identifying novel targets and biomarkers.
The platform’s “manifold folding” technique addresses a key challenge in large language models—hallucinations—by improving the accuracy of semantic retrieval. This innovation could enhance the reliability of AI-generated insights in drug development, where errors can lead to costly missteps. By indexing 28 million PubMed abstracts, PDAOAI provides researchers with a comprehensive knowledge base to support decision-making.
Oncotelic Therapeutics, a clinical-stage biopharmaceutical company focused on oncology and immunotherapy, also benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including a 45% interest in GMP Bio. This collaborative approach further strengthens its position in oncology and rare disease therapeutics.
The upcoming presentation at Qdrant Vector Space Day 2026 provides a platform for Oncotelic to demonstrate how AI can be practically applied to accelerate the development of treatments for high-unmet-need cancers. The implications for patients, investors, and the broader biotech industry are substantial, as faster development cycles could bring life-saving therapies to market sooner. For ongoing updates, refer to the company’s newsroom at https://ibn.fm/OTLC.
